ADXNZ Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.056 |
| 52 Week High | CHF 0.20 |
| 52 Week Low | CHF 0.038 |
| Beta | 1.87 |
| 11 Month Change | -32.69% |
| 3 Month Change | 0% |
| 1 Year Change | 29.63% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| ADXNZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -17.6% | -4.0% | 0.7% |
| 1Y | 29.6% | -18.9% | 6.1% |
Return vs Industry: ADXNZ exceeded the UK Biotechs industry which returned -18.9% over the past year.
Return vs Market: ADXNZ exceeded the UK Market which returned 6.1% over the past year.
Price Volatility
| ADXNZ volatility | |
|---|---|
| ADXNZ Average Weekly Movement | 18.4% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ADXNZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: ADXNZ's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
| ADXNZ fundamental statistics | |
|---|---|
| Market cap | CHF 5.54m |
| Earnings (TTM) | -CHF 11.86m |
| Revenue (TTM) | CHF 863.23k |
6.4x
P/S Ratio-0.5x
P/E RatioIs ADXNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADXNZ income statement (TTM) | |
|---|---|
| Revenue | CHF 863.23k |
| Cost of Revenue | CHF 6.97m |
| Gross Profit | -CHF 6.11m |
| Other Expenses | CHF 5.75m |
| Earnings | -CHF 11.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 22, 2024
| Earnings per share (EPS) | -0.12 |
| Gross Margin | -707.66% |
| Net Profit Margin | -1,373.53% |
| Debt/Equity Ratio | 0% |
How did ADXNZ perform over the long term?
See historical performance and comparison